Relation between Plasma Trough Concentration of Pazopanib and Progression-Free Survival in Metastatic Soft Tissue Sarcoma Patients

• Main Authors: Marie-Sophie (Author), Pascaline Boudou-Rouquette (Author), Anne Jouinot (Author), Sixtine de Percin (Author), David Balakirouchenane (Author), Nihel Khoudour (Author), Camille Tlemsani (Author), Jonathan Chauvin (Author), Audrey Thomas-Schoemann (Author), François Goldwasser (Author), Benoit Blanchet (Author), Jérôme Alexandre (Author)
• Format: Book
• Published: MDPI AG, 2022-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Background: Pazopanib (PAZ) is an oral angiogenesis inhibitor approved to treat soft tissue sarcoma (STS) but associated with a large interpatient pharmacokinetic (PK) variability and narrow therapeutic index. We aimed to define the specific threshold of PAZ trough concentration (C<sub>min<...